Show simple item record

dc.contributor.authorLaguna, Javier Muñoz
dc.contributor.authorBanegas, Jose R
dc.date.accessioned2022-06-29T20:47:57Z
dc.date.available2022-06-29T20:47:57Z
dc.date.issued2022-07-05
dc.identifier.citationMuñoz Laguna J, Banegas JR. Concerning “The HEARTS app: a clinical tool for cardiovascular risk and hypertension management in primary health care”. Rev Panam Salud Publica. 2022;46:e92. https://doi.org/10.26633/RPSP.2022.92en_US
dc.identifier.issn1680 5348
dc.identifier.urihttps://iris.paho.org/handle/10665.2/56130
dc.description.abstractDear editor, We read with interest the article entitled “The HEARTS app: a clinical tool for cardiovascular risk and hypertension management in primary health care” by Ordunez and colleagues, published on March 28th, 2022 (1). This article describes a recently developed app to assess cardiovascular disease (CVD) risk, as well as its use, potential functionality, and validation process. Despite the central role of the HEARTS initiative in the Americas and in the vulnerable region of Latin America and the Caribbean (LAC), we believe that the interpretation of the findings of this study requires some caution. There are some methodological issues in this manuscript that could compromise the strong conclusion that “the HEARTS app is an essential step in the journey towards eliminating preventable CVD in the Americas.” First, the risk prediction models that inform this app are derived from 85 cohorts from high-income countries in the Emerging Risk Factors Collaboration study (2). Of these, we were only able to identify the Puerto Rico Heart Health Program study as directly representative of the LAC region. Therefore, the lack of representativeness of the models for risk-prediction should be made more explicit. At the same time, the important role of the STEPwise approach to surveillance to obtain population-level indicators and trends, as well as calibration of the risk-prediction models should be both considered as potential solutions to this issue. Second, the authors state that “the app is intended to be used in clinical practice, especially at the primary health care level” although it can also “be used by anyone in the general population.” If the use of the app is available to the general public, this could systematically exclude underrepresented groups by creating differential engagement and generating digital inequity (3). Hence, the “ideal” target population of the app in low- and middle-income countries should be specified. Third, the language of the article should reflect the uncertainty regarding the long-term success of this digital health application in the region, which will likely depend on how it is implemented and maintained over time, and the promptness of the initiation of effective pharmacological treatment after the obtention of a risk score. Several barriers to the implementation of CVD risk calculators in primary care have been described, including time constraints, lack of electronic health records integration, and patient fears (4). Low-resource contexts potentially require tailoring of the app to address some of these barriers and ensure sustainability. The burden of CVD in LAC, estimated at 3 497.14 disabilityadjusted life years per 100 000 (range, 3 226.2 – 3 790.1), appears to be highly influenced by the years lived with disability due to ischemic heart disease (5) and by the increasing impact of high systolic blood-pressure (≥110-115 mmHg according to the Global Burden of Disease definition) as the leading mortality risk factor in the region. This public health scenario presents both a tremendous challenge and an opportunity for improvement. The HEARTS app is a promising driver of change. However, its validity should be evaluated in view of some methodological caveats and its implementation capacity should stress the letter “A” of its acronym to advocate for equitable “access to essential medicines and technology” in places where the availability and affordability of generic drugs is still scarce. To read the complete letter, please download the manuscript using the link on the left.en_US
dc.language.isoenen_US
dc.relation.ispartofseriesRev Panam Salud Publica;46, jul. 2022
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 IGO*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/igo/*
dc.subjectNoncommunicable Diseasesen_US
dc.subjectCardiovascular Diseasesen_US
dc.subjectHeart Disease Risk Factorsen_US
dc.subjectHypertensionen_US
dc.subjectMedical Informatics Applicationsen_US
dc.subjectQuality of Health Careen_US
dc.subjectAmericasen_US
dc.titleConcerning “The HEARTS app: a clinical tool for cardiovascular risk and hypertension management in primary health care”en_US
dc.typeJournal articlesen_US
dc.rights.holderPan American Health Organizationen_US
paho.articletypeLettersen_US
paho.isfeatured0en_US
dc.identifier.doihttps://doi.org/10.26633/RPSP.2022.92
paho.source.centercodeUS1.1en_US
dc.relation.ispartofjournalRevista Panamericana de Salud Públicaes_ES
dc.relation.ispartofjournalPan American Journal of Public Health


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 3.0 IGO
This notice should be preserved along with the article's original URL.Attribution-NonCommercial-ShareAlike 3.0 IGO